Morgan Stanley lowered the firm’s price target on Cooper Companies to $355 from $410 and keeps an Equal Weight rating on the shares. A combination of rising 10 year rates and GLP-1 pressures have pushed the valuation of the U.S. MedTech sector down and given the material de-rating the firm is upgrading its Industry View on MedTech to Attractive, the analyst tells investors. Volumes remain in strong shape, capital equipment is looking healthy and the firm sees limited expected impact from GLP-1s, the analyst added in a note on the group in which the firm adjusted a number of price targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on COO:
- CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2023
- CooperCompanies Expands CooperSurgical’s Medical Device Portfolio with Acquisition of Select Cook Medical® Assets
- AbbVie upgraded, Cisco downgraded: Wall Street’s top analyst calls
- Cooper Companies initiated with a Buy at BofA
- Cooper Companies price target lowered to $390 from $440 at Mizuho
Questions or Comments about the article? Write to editor@tipranks.com